PT-141 (Bremelanotide) for Male Sexual Dysfunction: Off-Label Dosing Protocol

What Is Bremelanotide and Why Is It Used Off-Label in Men?

Bremelanotide is a synthetic cyclic heptapeptide that activates melanocortin receptors, primarily MC4R, in the hypothalamus and limbic system. Unlike PDE5 inhibitors such as sildenafil and tadalafil, which act on peripheral vascular smooth muscle, bremelanotide works through central nervous system pathways that regulate sexual arousal and desire 1. The FDA approved it in June 2019 under the brand name Vyleesi for premenopausal women with acquired, generalized HSDD 2.

Why Clinicians Consider It for Men

Male sexual dysfunction encompasses erectile dysfunction (ED), hypoactive sexual desire disorder, and anorgasmia. PDE5 inhibitors remain first-line for ED, but they address hemodynamics, not desire 3. Men who report adequate blood flow but diminished libido or arousal represent a clinical gap. Bremelanotide's mechanism of action targets this gap by engaging central arousal circuits independent of nitric oxide signaling 4.

Regulatory Status

No manufacturer has submitted a New Drug Application for bremelanotide in men. Palatin Technologies, the developer, completed phase II studies in males but redirected the phase III program toward the female HSDD indication 5. Any use of bremelanotide in men is off-label, and prescribers should document the clinical rationale and obtain informed consent.

Clinical Evidence in Men: What the Trials Show

The evidence base for bremelanotide in male sexual dysfunction is limited to early-phase trials. No phase III randomized controlled trial has been completed for any male indication. Prescribers should interpret the data accordingly.

The Diamond et al. Phase II Study (2004)

The most frequently cited male trial is the 2004 placebo-controlled, crossover study by Diamond and colleagues. This study enrolled men with ED (N=20, mean age 50) who had documented erectile response to visual sexual stimulation. Participants received bremelanotide 4 mg or 10 mg subcutaneously versus placebo in a randomized crossover design. The primary endpoint was rigidity measured by RigiScan 6.

Results showed that the 10 mg dose produced a clinically meaningful increase in penile rigidity. Tip rigidity exceeded 60% (the threshold for penetration) in 67% of subjects on 10 mg versus 23% on placebo (P<0.05). The 4 mg dose showed a trend toward improvement but did not reach statistical significance 6.

Intranasal Formulation Data

Earlier studies tested bremelanotide via intranasal spray at doses of 7 mg and 20 mg. A 2005 at-home study (N=271) using the intranasal route demonstrated a significant improvement in erectile function scores on the International Index of Erectile Function (IIEF) compared to placebo 7. The intranasal route was eventually abandoned after the FDA raised concerns about unpredictable blood pressure elevations at higher doses 8.

Melanocortin Receptor Pharmacology

Preclinical studies established that MC4R activation in the paraventricular nucleus induces penile erection in rodent and primate models through descending autonomic pathways, distinct from the peripheral NO/cGMP pathway targeted by PDE5 inhibitors 9. This central mechanism is why bremelanotide may benefit men whose dysfunction is primarily desire-based or psychogenic rather than vasculogenic 4.

Off-Label Dosing Protocol for Men

No FDA-approved dosing exists for men. The protocols described here are derived from published clinical trial data and should be interpreted as investigational. Any prescribing decision requires individualized risk-benefit assessment.

Subcutaneous Injection: Dose and Timing

Based on the Diamond et al. Trial and Palatin Technologies' clinical development data, the dose range studied in men was 1 mg to 10 mg subcutaneously 6. Most clinicians who prescribe off-label report using doses between 1.5 mg and 2 mg as a starting point, titrating to effect.

The female-labeled dose is 1.75 mg subcutaneously, administered at least 45 minutes before anticipated sexual activity 2. Some off-label male protocols begin at 1.75 mg and adjust based on tolerability.

Key parameters from published data:

• Route: subcutaneous injection in the abdomen or thigh
• Onset: 30 to 60 minutes; peak plasma concentration at approximately 1 hour 10
• Duration of effect: clinical effects observed for 6 to 12 hours in trial settings
• Dosing cap: no more than one dose in 24 hours; no more than 8 doses per month per the female FDA label 2

Starting Low and Titrating

A conservative approach involves starting at 0.5 mg to 1.0 mg to evaluate nausea tolerance before escalating to 1.5 mg or 1.75 mg. Men in the phase II trials who received 10 mg experienced higher rates of nausea (over 40%) and significant blood pressure elevation 6. Lower doses reduce these risks while potentially preserving the central arousal effect.

Why Intranasal Dosing Was Abandoned

The intranasal route allowed doses up to 20 mg but produced erratic pharmacokinetics and prompted an FDA clinical hold in 2007 due to blood pressure concerns 8. Subcutaneous injection became the sole development route after this hold was resolved 5.

Safety Profile and Monitoring Requirements

Bremelanotide carries specific safety signals that require monitoring, particularly in male patients who may have unrecognized cardiovascular risk factors.

Nausea

Nausea is the most common adverse event. In the female RECONNECT trials, 40% of bremelanotide-treated patients reported nausea versus 1% on placebo 11. Male trial data showed similar rates at higher doses. The nausea is typically self-limiting, peaking within 1 to 2 hours and resolving within 4 hours. Pre-treatment with ondansetron 4 mg orally has been used clinically to mitigate this, though this combination has not been studied in controlled trials.

Blood Pressure Elevation

Bremelanotide produces a transient increase in systolic blood pressure of approximately 6 mmHg and a decrease in heart rate of approximately 5 bpm, peaking 2 to 4 hours after injection 2. The FDA label contraindicates Vyleesi in patients with uncontrolled hypertension or known cardiovascular disease 2. For men being considered for off-label use, baseline blood pressure screening and periodic monitoring are appropriate.

Skin Hyperpigmentation

Focal hyperpigmentation of the face, gums, and breasts occurred in approximately 1% of patients in the RECONNECT trials and was attributed to MC1R activation 11. This effect may be more pronounced with chronic use and should be discussed during informed consent.

Monitoring Checklist for Off-Label Male Use

Before initiating bremelanotide in men:

• Confirm baseline blood pressure is below 140/90 mmHg
• Screen for uncontrolled cardiovascular disease, including recent MI or unstable angina
• Document concurrent medications, particularly antihypertensives and PDE5 inhibitors
• Obtain informed consent specifying off-label status and limited evidence
• Reassess blood pressure at follow-up after the first 2 to 3 doses

How Bremelanotide Compares to PDE5 Inhibitors

The clinical decision between bremelanotide and PDE5 inhibitors depends on the etiology of the dysfunction. These agents work through entirely different pathways and may be complementary in select patients.

Mechanism Differences

PDE5 inhibitors (sildenafil, tadalafil, vardenafil) block the degradation of cGMP in corpus cavernosum smooth muscle, producing vasodilation 3. They require sexual stimulation and intact nitric oxide signaling to work. Bremelanotide acts centrally on MC4R to increase arousal and desire independent of peripheral vascular status 1.

When PDE5 Inhibitors Fall Short

Approximately 30% to 35% of men with ED do not respond adequately to PDE5 inhibitors 12. Causes of non-response include severe vascular disease, radical prostatectomy-related nerve injury, and psychogenic factors. For men whose primary complaint is diminished desire rather than hemodynamic insufficiency, a centrally acting agent like bremelanotide addresses a different component of the sexual response cycle.

Combination Use Considerations

No published trial has evaluated concurrent bremelanotide and PDE5 inhibitor use in men. The FDA label for Vyleesi does not list PDE5 inhibitors as contraindicated, but the blood pressure effects of both drug classes warrant caution 2. Men taking nitrates remain absolutely contraindicated from PDE5 inhibitor use and should not receive bremelanotide without careful cardiovascular evaluation 13.

Patient Selection: Who Might Benefit Most

Not every man with sexual dysfunction is a candidate for off-label bremelanotide. Selecting the right patient requires differentiating between desire-phase and arousal-phase problems.

Strongest Potential Candidates

Men most likely to benefit include those with:

• Low sexual desire confirmed by a validated instrument (e.g., Sexual Desire Inventory)
• Adequate erectile response to PDE5 inhibitors but persistent lack of interest in sexual activity
• Psychogenic ED with intact peripheral vascular function confirmed by nocturnal penile tumescence testing
• Hypogonadal men on testosterone replacement who still report low desire after testosterone levels normalize 14

Poor Candidates

Men with severe organic ED from radical prostatectomy nerve injury, significant peripheral vascular disease, or uncontrolled diabetes are unlikely to benefit from a centrally acting agent alone. These patients need peripheral interventions such as intracavernosal injections, vacuum erection devices, or penile prosthesis placement 15.

The Role of Testosterone

Testosterone deficiency is the most common endocrine cause of male hypoactive sexual desire. The Endocrine Society recommends measuring morning total testosterone before attributing low desire to other causes 16. Bremelanotide should not be used as a substitute for testosterone replacement in hypogonadal men. Instead, it may serve as an adjunct when desire remains low despite testosterone normalization.

What the Evidence Grade Means for Clinical Practice

By GRADE criteria, the evidence for bremelanotide in male sexual dysfunction is rated low. This reflects the absence of phase III data, small sample sizes in completed trials (N=20 to N=271), and the lack of long-term safety data in male populations.

What "Low Evidence" Does Not Mean

A low GRADE rating does not mean the drug is ineffective. It means the confidence in the estimated effect is limited, and additional research could substantially change the estimate 17. The pharmacologic rationale for MC4R agonism in male sexual function is mechanistically sound, supported by preclinical data and proof-of-concept human trials.

Documentation Requirements

Clinicians prescribing bremelanotide off-label should document:

• The evidence base reviewed and discussed with the patient
• The rationale for choosing bremelanotide over approved alternatives
• The specific dose, route, and frequency prescribed
• Informed consent acknowledging off-label status

The American Urological Association does not include bremelanotide in its ED treatment guidelines 15. This absence reinforces the importance of thorough documentation.

Practical Considerations: Access and Cost

Vyleesi is available as a pre-filled autoinjector containing 1.75 mg of bremelanotide in 0.3 mL. The wholesale acquisition cost for a single-use autoinjector is approximately $900 to $1,000 for a pack of four, though pricing varies by pharmacy. Insurance coverage for off-label male use is rare.

Compounded Formulations

Some compounding pharmacies dispense bremelanotide in multi-dose vials, typically at concentrations of 10 mg/mL. Compounded formulations are not FDA-approved and lack the quality controls of commercially manufactured products 18. Patients using compounded bremelanotide should be counseled about the regulatory distinction and the importance of sourcing from a 503B outsourcing facility registered with the FDA.

Storage and Handling

The commercially available autoinjector should be stored at 20°C to 25°C (68°F to 77°F) and protected from light. Compounded vials typically require refrigeration at 2°C to 8°C after reconstitution, with a beyond-use date determined by the compounding pharmacy 2.